Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
Open Access
- 26 January 2018
- journal article
- research article
- Published by Wiley in Obesity Science & Practice
- Vol. 4 (2) , 141-152
Abstract
Summary: Objective: This multicenter, randomized, controlled, open‐label trial examined weight‐related quality of life, control over eating behaviour and sexual function after 26 weeks of treatment with either 32 mg naltrexone sustained release (SR)/360 mg bupropion SR plus a comprehensive lifestyle intervention program (NB + CLI, N = 153) or usual care (UC, N = 89), which included minimal lifestyle intervention.Methods: Impact of Weight on Quality of Life‐Lite, Binge Eating Scale and Arizona Sexual Experiences Scale were assessed at baseline (BL) and weeks 16 and 26.Results: NB + CLI and UC participants lost 9.46 and 0.94% respectively of initial body weight at week 26 (P < 0.0001). NB + CLI participants had greater improvements in Impact of Weight on Quality of Life‐Lite total score than UC participants (P < 0.0001). In participants with moderate/severe Binge Eating Scale scores at BL, 91% of NB + CLI and 18% of UC participants experienced categorical improvements. In participants with Arizona Sexual Experiences Scale‐defined sexual dysfunction at BL, 58% of NB + CLI and 19% of UC participants no longer met dysfunction criteria at week 26. The most frequent adverse events leading to discontinuation before week 26 in NB + CLI included nausea (10.5%); anxiety (3.3%); and headache, hypertension, insomnia and palpitations (1.3% each).Conclusion: Compared with UC, participants treated with NB + CLI experienced greater improvements in weight‐related quality of life, control over eating behaviour, and sexual function.Keywords
Funding Information
- Orexigen Therapeutics, Inc.
This publication has 40 references indexed in Scilit:
- Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive DisorderThe Primary Care Companion For CNS Disorders, 2013
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)Obesity, 2013
- Efficacy of rimonabant in obese patients with binge eating disorderExperimental and Clinical Endocrinology & Diabetes, 2012
- Significant resolution of female sexual dysfunction after bariatric surgerySurgery for Obesity and Related Diseases, 2011
- Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research studyAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- A comparison of the binge eating scale, questionnaire for eating and weight patterns‐revised, and eating disorder examination questionnaire with instructions with the eating disorder examination in the assessment of binge eating disorder and its symptomsInternational Journal of Eating Disorders, 2004
- An integrated method to determine meaningful changes in health-related quality of lifeJournal of Clinical Epidemiology, 2004
- Binge eating disorder and obesityInternational Journal of Obesity, 2001
- The Arizona Sexual Experience Scale (ASEX): Reliability and ValidityJournal of Sex & Marital Therapy, 2000
- Assessing Impact of Weight on Quality of LifeObesity Research, 1995